Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
cancer (8) 8
index medicus (6) 6
surgery (6) 6
aged (5) 5
carcinoma (5) 5
chemotherapy (5) 5
gastroenterology & hepatology (5) 5
middle aged (5) 5
neoadjuvant therapy (5) 5
therapy (5) 5
tumor proteins (5) 5
apoptosis (4) 4
cardiac & cardiovascular systems (4) 4
female (4) 4
adult (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biopsy (3) 3
breast neoplasms - genetics (3) 3
breast neoplasms - pathology (3) 3
care and treatment (3) 3
cisplatin - administration & dosage (3) 3
combined modality therapy (3) 3
esophageal cancer (3) 3
expression (3) 3
genes, p53 - genetics (3) 3
genetic aspects (3) 3
genotype (3) 3
liver cancer (3) 3
lung neoplasms - genetics (3) 3
medicine & public health (3) 3
metastasis (3) 3
mutations (3) 3
polymerase chain reaction (3) 3
predictive value of tests (3) 3
respiratory system (3) 3
abridged index medicus (2) 2
adenocarcinoma - genetics (2) 2
adenocarcinoma - pathology (2) 2
animals (2) 2
antineoplastic agents - therapeutic use (2) 2
biomarkers, tumor - genetics (2) 2
breast neoplasms - drug therapy (2) 2
carcinoma, hepatocellular - genetics (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
cardiology and cardiovascular medicine (2) 2
cardiothoracic surgery (2) 2
cell line, tumor (2) 2
chemoradiotherapy (2) 2
core needle biopsy (2) 2
dna methylation (2) 2
dna mutational analysis (2) 2
esophageal neoplasms - pathology (2) 2
esophageal neoplasms - therapy (2) 2
esophagus (2) 2
fibroblasts (2) 2
fish (2) 2
growth factors (2) 2
hepatocarcinogenesis (2) 2
her-2/neu (2) 2
her2/neu (2) 2
immunohistochemistry (2) 2
in situ hybridization, fluorescence (2) 2
liver neoplasms - genetics (2) 2
lung cancer, non-small cell (2) 2
male (2) 2
medical colleges (2) 2
minimally invasive esophagectomy (2) 2
mutation (2) 2
neoadjuvant chemoradiation (2) 2
neoplasm staging (2) 2
oncology (2) 2
oncology, experimental (2) 2
p53 (2) 2
phenotype (2) 2
positron-emission-tomography (2) 2
predictive marker (2) 2
prognosis (2) 2
pulmonary and respiratory medicine (2) 2
receptor (2) 2
research (2) 2
robots (2) 2
rodents (2) 2
survival (2) 2
survival analysis (2) 2
trastuzumab (2) 2
treatment outcome (2) 2
up-regulation (2) 2
5-fu (1) 1
5-methylcytosine (1) 1
5‐fu (1) 1
abdominal surgery (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma - therapy (1) 1
adenovirus vector (1) 1
adenoviruses (1) 1
aeg (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study
by Kandioler, Daniela, MD, MBA and Schoppmann, Sebastian F., MD and Zwrtek, Ronald, MD and Kappel, Sonja, PhD and Wolf, Brigitte, PhD and Mittlböck, Martina, PhD and Kührer, Irene, MD and Hejna, Michael, MD and Pluschnig, Ursula, MD and Ba-Ssalamah, Ahmed, MD and Wrba, Fritz, MD and Zacherl, Johannes, MD
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2014, Volume 148, Issue 5, pp. 2280 - 2286
Background Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer. Both drugs are believed to act via a... 
Cardiothoracic Surgery | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | GENOTYPE | GUIDELINES | VALIDATION | CHEMORADIOTHERAPY | PATTERNS | IMMUNOHISTOCHEMICAL RESULT | CHEMOTHERAPY | PREDICTIVE MARKER | RESPIRATORY SYSTEM | MUTATION | CARCINOMA | Predictive Value of Tests | Adenocarcinoma - pathology | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Male | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Austria | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Esophageal Neoplasms - mortality | Female | Neoadjuvant Therapy | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Genetic Predisposition to Disease | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagectomy | Treatment Outcome | Adenocarcinoma - drug therapy | Phenotype | Carcinoma, Squamous Cell - drug therapy | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Biomarkers, Tumor - genetics | Mutation | Esophageal Neoplasms - drug therapy | Adenocarcinoma - mortality | Care and treatment | Cancer patients | Patient outcomes | Gastrointestinal diseases | Oncology, Experimental | Research | Tumor proteins | Esophageal cancer | Cancer | Fluorouracil
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer
by Kandioler, Daniela, MD and Stamatis, Georgios, MD and Eberhardt, Wilfried, MD and Kappel, Sonja, PhD and Zöchbauer-Müller, Sabine, MD and Kührer, Irene, MD and Mittlböck, Martina, PhD and Zwrtek, Ronald, MD and Aigner, Clemens, MD and Bichler, Christoph, JD and Tichy, Victoria, JD and Hudec, Marcus, PhD and Bachleitner, Thomas, MD and End, Adelheid, MD and Müller, Michael Rolf, MD and Roth, Erich, PhD and Klepetko, Walter, MD
The Journal of Thoracic and Cardiovascular Surgery, ISSN 0022-5223, 2008, Volume 135, Issue 5, pp. 1036 - 1041
Objective The objective of this study is to establish clinical evidence that the p53 genotype can serve as a predictive marker for response to cisplatin-based... 
Cardiothoracic Surgery | TRIAL | SURGERY | SURVIVAL | CHEMOSENSITIVITY | APOPTOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | RESPIRATORY SYSTEM | FOLLOW-UP | TUMORS | COMPARING PERIOPERATIVE CHEMOTHERAPY | Lung Neoplasms - genetics | Predictive Value of Tests | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Etoposide - administration & dosage | Genotype | Treatment Outcome | Combined Modality Therapy | Lung Neoplasms - therapy | Genes, p53 - genetics | Pneumonectomy | Cisplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Neoadjuvant Therapy | Aged | Biomarkers, Tumor - genetics | Radiotherapy, Adjuvant | Clinical Trials, Phase II as Topic | Medical colleges | Chemotherapy | Genetic aspects | Tumor proteins | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer
by Kandioler-Eckersberger, Daniela and Kappel, S and Mittlböck, M and Dekan, G and Ludwig, C and Janschek, E and Pirker, R and Wolner, E and Eckersberger, F
The Journal of Thoracic and Cardiovascular Surgery, ISSN 0022-5223, 1999, Volume 117, Issue 4, pp. 744 - 750
The cytotoxic effects of cisplatin and anthracyclins have been attributed to apoptosis induction, which has been recognized as a major function of the gene.... 
SURGERY | APOPTOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | RESPIRATORY SYSTEM | TUMOR-SUPPRESSOR GENE | CLUES | MUTATIONS | CHEMOTHERAPY | RANDOMIZED TRIAL | P53 | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Genotype | Genes, p53 - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Case-Control Studies | Cisplatin - administration & dosage | Tumor Suppressor Protein p53 - analysis | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Polymerase Chain Reaction | Survival Analysis | Neoadjuvant Therapy | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Chemotherapy | Genetic aspects | Tumor proteins | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Stage-directed individualized therapy in esophageal cancer
by Goense, Lucas and van Rossum, Peter S N and Kandioler, Daniela and Ruurda, Jelle P and Goh, Khean Lee and Luyer, Misha D and Krasna, Mark J and van Hillegersberg, Richard
Annals of the New York Academy of Sciences, ISSN 0077-8923, 10/2016, Volume 1381, Issue 1, pp. 50 - 65
Esophageal cancer is the eighth most common cancer worldwide, and the incidence of esophageal carcinoma is rapidly increasing. With the advent of new staging... 
esophageal cancer | esophageal surgery | tumor staging | History and Philosophy of Science | anastomotic leakage | Biochemistry, Genetics and Molecular Biology(all) | Review | robot-assisted | Journal Article | neoadjuvant chemoradiation | robot‐assisted | CERVICAL ANASTOMOTIC LEAKS | RANDOMIZED CLINICAL-TRIAL | PET-CT | PATHOLOGICAL COMPLETE RESPONSE | PHASE-III TRIAL | MINIMALLY INVASIVE ESOPHAGECTOMY | POSITRON-EMISSION-TOMOGRAPHY | LYMPH-NODE METASTASIS | NEOADJUVANT CHEMORADIOTHERAPY | SQUAMOUS-CELL CARCINOMA | GASTROENTEROLOGY & HEPATOLOGY | Humans | Esophageal Neoplasms - diagnosis | Antineoplastic Agents - therapeutic use | Combined Modality Therapy - methods | Esophagectomy - methods | Esophageal Neoplasms - therapy | Neoplasm Staging | Precision Medicine - methods | Care and treatment | Health aspects | Esophageal cancer | Cancer | Health risk assessment | Biopsy | Esophageal carcinoma | Cervix | Lymph nodes | Incidence | Esophagus | Endoscopes | Surgery | Dissection | Robots | Lymph
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors
by Kandioler, Daniela and Dekan, Gerhard and End, Adelheid and Paschinga, Eva and Buchmayer, Heidi and Gnant, Michael and Langmann, Florian and Mannhalter, Christine and Eckersberger, Franz and Wolner, Ernst
The Journal of Thoracic and Cardiovascular Surgery, ISSN 0022-5223, 1996, Volume 111, Issue 4, pp. 827 - 832
When solitary pulmonary tumors are observed in patients with a history of cancer, differentiation between metastasis and primary lung cancer is crucial for... 
SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | MUTATIONS | P53 GENE | Lung Neoplasms - genetics | Colonic Neoplasms - genetics | Kidney Neoplasms - genetics | Humans | Lung Neoplasms - pathology | Genes, p53 - genetics | Adenocarcinoma - secondary | Thyroid Neoplasms - genetics | Breast Neoplasms - genetics | Rectal Neoplasms - genetics | Lung Neoplasms - secondary | Breast Neoplasms - pathology | DNA Mutational Analysis | Colonic Neoplasms - pathology | Polymerase Chain Reaction | Kidney Neoplasms - pathology | Adenocarcinoma - genetics | Rectal Neoplasms - pathology | Thyroid Neoplasms - pathology | Polymerase chain reaction | Care and treatment | Thyroid cancer | Analysis | Genetic research | Genetic aspects | Metastasis | Tumor proteins | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?
by Paur, Jakob and Nika, Lisa and Maier, Christiane and Moscu‐Gregor, Alexander and Kostka, Julia and Huber, Daniela and Mohr, Thomas and Heffeter, Petra and Schrottmaier, Waltraud C and Kappel, Sonja and Kandioler, Daniela and Holzmann, Klaus and Marian, Brigitte and Berger, Walter and Grusch, Michael and Grasl‐Kraupp, Bettina
Hepatology, ISSN 0270-9139, 12/2015, Volume 62, Issue 6, pp. 1767 - 1778
Fibroblast growth factor receptors (FGFRs) are frequently up‐regulated in subsets of hepatocellular carcinoma (HCC). Here, we provide mechanistic insight that... 
CELLS | COMPLEX | METASTASIS | SPECIFICITY | PHENOTYPE | INHIBITOR | NVP-BGJ398 | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | INSIGHTS | FAMILY | Up-Regulation | Humans | Liver Neoplasms - drug therapy | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Mice, SCID | Liver Neoplasms - etiology | Receptor, Fibroblast Growth Factor, Type 3 - physiology | Animals | Carcinoma, Hepatocellular - drug therapy | Protein Isoforms | Carcinoma, Hepatocellular - etiology | Mice | Tumor Cells, Cultured | Fibroblasts | Liver cancer | Growth factors | Rodents | Endothelium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis
by Gauglhofer, Christine and Sagmeister, Sandra and Schrottmaier, Waltraud and Fischer, Carina and Rodgarkia‐Dara, Chantal and Mohr, Thomas and Stättner, Stefan and Bichler, Christoph and Kandioler, Daniela and Wrba, Fritz and Schulte‐Hermann, Rolf and Holzmann, Klaus and Grusch, Michael and Marian, Brigitte and Berger, Walter and Grasl‐Kraupp, Bettina
Hepatology, ISSN 0270-9139, 03/2011, Volume 53, Issue 3, pp. 854 - 864
Fibroblast growth factors (FGFs) and their high‐affinity receptors [fibroblast growth factor receptors (FGFRs)] contribute to autocrine and paracrine growth... 
FACTOR FAMILY | THERAPY | INFLAMMATION | AUTOCRINE | ENDOTHELIAL-CELLS | LIVER | PROLIFERATION | FGF FAMILY | GASTROENTEROLOGY & HEPATOLOGY | CANCER | HEPATOCARCINOGENESIS | Up-Regulation | Liver Neoplasms - genetics | Humans | Receptors, Fibroblast Growth Factor - biosynthesis | Cell Survival - genetics | Rats | Tumor Microenvironment | Proto-Oncogene Proteins c-akt - physiology | Fibroblast Growth Factor 8 - metabolism | Fibroblast Growth Factors - metabolism | Animals | Mitogen-Activated Protein Kinases - physiology | Carcinoma, Hepatocellular - genetics | Cell Line, Tumor | Hypoxia - physiopathology | Neovascularization, Pathologic - genetics | Fibroblasts | Liver cancer | Growth factors | Rodents | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Barrett's esophagus: treatments of adenocarcinomas II
by Twaddell, William S and Wu, Peter C and Verhage, Roy J.J and Feith, Marcus and Ilson, David H and Schuhmacher, Christoph P and Luketich, James D and Brücher, Björn and Vallböhmer, Daniel and Hofstetter, Wayne L and Krasna, Mark Jonathan and Kandioler, Daniela and Schneider, Paul M and Wijnhoven, Bas P.L and Sontag, Stephen J
Annals of the New York Academy of Sciences, ISSN 0077-8923, 09/2011, Volume 1232, Issue 1, pp. 265 - 291
The following topics are explored in this collection of commentaries on treatments of adenocarcinomas related to Barrett's esophagus: the importance of... 
esophageal cancer | integrated PET/CT scan | EGFR | FDG PET scan | p53 | adenovirus vector | two‐stade esophagectomy | sentinel node | Barrett's esophagus | robot assisted thoracolaparoscopic esophagectomy | high risk patients | 5‐FU | cisplatin | FOLFOX | AEG | sentinel lymph nodes | gamma probe | residual disease | R0 resection | chemoradiotherapy | adenocarcinoma | gefitinib | prognosis | lymphadenectomy | robotic surgery | neoadjuvant chemotherapy | radiotherapy | Siewert 's classification | multimodality therapy | PET tracer | HER2 | minimally invasive esophagectomy | chemoradiation | molecular markers | submucosal invasion | Adenocarcinoma | Neoadjuvant chemotherapy | Prognosis | Sentinel lymph nodes | Minimally invasive esophagectomy | Residual disease | Chemoradiotherapy | Two-stade esophagectomy | Lymphadenectomy | Molecular markers | Chemoradiation | Sentinel node | Gefitinib | Submucosal invasion | Gamma probe | Radiotherapy | Robot assisted thoracolaparoscopic esophagectomy | Cisplatin | P53 | Robotic surgery | Adenovirus vector | Multimodality therapy | High risk patients | Integrated PET/CT scan | Esophageal cancer | 5-FU | GASTROESOPHAGEAL JUNCTION | SURGICAL THERAPY | PATHOLOGICAL RESPONSE | NEOADJUVANT CHEMORADIATION | GASTROINTESTINAL CANCER | two-stade esophagectomy | ESOPHAGOGASTRIC JUNCTION | HISTOPATHOLOGIC RESPONSE | SENTINEL LYMPH-NODE | MULTIDISCIPLINARY SCIENCES | POSITRON-EMISSION-TOMOGRAPHY | TARGETED AGENTS | GASTROENTEROLOGY & HEPATOLOGY | Adenocarcinoma - pathology | Barrett Esophagus - pathology | Adenocarcinoma - therapy | Humans | Survival Analysis | Combined Modality Therapy | Sentinel Lymph Node Biopsy | Esophageal Neoplasms - therapy | Esophageal Neoplasms - pathology | Chemotherapy | Dysplasia | PET imaging | Tracers (Biology) | Adenoviruses | Monoclonal antibodies | Drug therapy | Tumor proteins | Robots | Cancer | Biopsy | Mortality | Therapy | Indication | Assessments | Frozen | Patients | Esophagus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma
by Macheiner, Doris and Heller, Gerwin and Kappel, Sonja and Bichler, Christoph and Stättner, Stefan and Ziegler, Barbara and Kandioler, Daniela and Wrba, Fritz and Schulte-Hermann, Rolf and Zöchbauer-Müller, Sabine and Grasl-Kraupp, Bettina
Journal of Hepatology, ISSN 0168-8278, 2006, Volume 45, Issue 1, pp. 81 - 89
In human hepatocellular carcinoma (HCC) the ras-proto-oncogene is rarely mutated. We therefore studied the possible inactivation of the putative... 
NORE1B | RASSF1A | Epigenetic gene silencing | Human hepatocellular carcinoma | LUNG | PROTEIN | RAS | epigenetic gene silencing | HEPATOCARCINOGENESIS | INACTIVATION | GENE | CELL-CYCLE | HUMAN CANCERS | GASTROENTEROLOGY & HEPATOLOGY | human hepatocellular carcinoma | EXPRESSION | Liver Neoplasms - genetics | Humans | Middle Aged | Gene Silencing | Male | Carcinoma, Hepatocellular - enzymology | Monomeric GTP-Binding Proteins - genetics | DNA Methylation | Globins - genetics | Carcinoma, Hepatocellular - genetics | Cell Division | Carcinoma, Hepatocellular - pathology | Polymerase Chain Reaction | Cell Line, Tumor | Adult | Female | Liver Neoplasms - pathology | Aged | DNA, Neoplasm - genetics | Liver Neoplasms - enzymology | Genes, Tumor Suppressor | Proteins | Medical colleges | Liver cancer | Oncology, Experimental | Research | Hepatoma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer
by Matthias, Wielscher and Liou, Willy and Pulverer, Walter and Singer, Christian F and Rappaport-Fuerhauser, Christine and Kandioler, Daniela and Egger, Gerda and Weinhäusel, Andreas
Translational Oncology, ISSN 1936-5233, 2013, Volume 6, Issue 6, pp. 715 - IN27
Change of DNA cytosine methylation (5mC) is an early event in the development of cancer, and the recent discovery of a 5-hydroxymethylated form (5hmC) of... 
Oncology | MODIFIER | METASTASIS | MELANOMA | DNA METHYLATION | 5-METHYLCYTOSINE | CHROMATIN | ONCOLOGY | FEZ1/LZTS1 | DOWN-REGULATION | MUTATIONS | CARCINOMA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected
by Kappel-Latif, Sonja and Zacherl, Johannes and Hejna, Michael and Westerhoff, Maria and Tamandl, Dietmar and Ba-Ssalamah, Ahmed and Mittlböck, Martina and Wolf, Brigitte and Wrba, Friedrich and Kührer, Irene and Pluschnig, Ursula and Schoppmann, Sebastian F and Függer, Reinhold and Zwrtek, Ronald and Glaser, Karl and Karner, Josef and Längle, Friedrich and Wenzl, Etienne and Roka, Rudolf and Öfner, Dietmar and Tschmelitsch, Jörg and Hold, Michael and Keil, Felix and Gnant, Michael and Kandioler, Daniela and Pancho Trialists Med University Vi and Pancho trialists and for the Medical University of Vienna p53research group and the Pancho trialists and for the Medical University of Vienna p53research group
European Surgery, ISSN 1682-8631, 8/2018, Volume 50, Issue 4, pp. 160 - 166
In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first... 
Randomized biomarker trial | Medicine & Public Health | Cardiac Surgery | Surgery | Abdominal Surgery | Vascular Surgery | Mark53 | General Surgery | Response prediction | Predictive marker | SURVIVAL | SURGERY | PREOPERATIVE CHEMORADIATION | THERAPY | CARCINOMA | PREDICTION | Short Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer
by Taucher, Susanne and Rudas, Margaretha and Mader, Robert M and Gnant, Michael and Sporn, Emanuel and Dubsky, Peter and Roka, Sebastian and Bachleitner, Thomas and Fitzal, Florian and Kandioler, Daniela and Wenzel, Catharina and Steger, Günther G and Mittlböck, Martina and Jakesz, Raimund
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2003, Volume 82, Issue 3, pp. 207 - 213
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration... 
trastuzumab | Medicine & Public Health | docetaxel | preoperative treatment | FISH | HER2/ neu | Oncology | breast cancer | epirubicin | immunohistochemistry | core needle biopsy | Immunohistochemistry | Docetaxel | Breast cancer | Core needle biopsy | Epirubicin | HER2/neu | Preoperative treatment | Trastuzumab | APOPTOSIS | DOXORUBICIN | MARKERS | RECEPTOR | BIOPSY SPECIMENS | CHEMOTHERAPY | PACLITAXEL | ONCOLOGY | HER-2/NEU | CORE BIOPSY | CARCINOMA | Biomarkers, Tumor - analysis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | In Situ Hybridization, Fluorescence | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Adult | Female | Neoadjuvant Therapy | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights